Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma : a NICE single technology appraisal.

Saved in:
Bibliographic Details
Title: Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma : a NICE single technology appraisal.
Authors: Kilonzo M; Health Economics Research Unit, Institute of Applied Health Sciences, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen, AB25 2ZD, UK. m.kilonzo@abdn.ac.uk, Hislop J, Elders A, Fraser C, Bissett D, McClinton S, Mowatt G, Vale L
Source: PharmacoEconomics [Pharmacoeconomics] 2013 Jan; Vol. 31 (1), pp. 15-24.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
Journal Info: Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 9212404 Publication Model: Print Cited Medium: Internet ISSN: 1179-2027 (Electronic) Linking ISSN: 11707690 NLM ISO Abbreviation: Pharmacoeconomics
Database: MEDLINE Ultimate
Description
ISSN:1179-2027
DOI:10.1007/s40273-012-0006-5